中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 7
Jul.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(7): 1469-1475

Inducing ferroptosis：A novel strategy to reverse gemcitabine resistance in pancreatic cancer

DOI: 10.12449/JCH250737

  • Department of Hepatobiliary Pancreatic and Splenic Surgery，Changhai Hospital，Navyl Medical University，Shanghai 200433，China

Research funding:

General Project of National Natural Science Foundation of China (82172712);

General Incubation Program of Basic Medical Research of Naval Medical University (2022MS013)

More Information
  • Corresponding author: ZHENG Kailian， zhengkl828@126.com （ORCID： 0000-0002-7341-0639）
  • Received Date: 2024-10-07
  • Accepted Date: 2024-12-04
  • Published Date: 2025-07-25
    Abstract

  • Pancreatic cancer is a highly malignant tumor of the digestive system， with a significantly lower five-year survival rate than other malignancies. Gemcitabine （GEM） is the primary chemotherapeutic agent for pancreatic cancer， but its efficacy is often limited by chemotherapy resistance of tumor. This article elaborates on the intrinsic cellular mechanism and non-cell-autonomous mechanism of GEM resistance in pancreatic cancer and summarizes how to enhance the sensitivity of pancreatic cancer cells to GEM by inducing ferroptosis through the regulation of polyunsaturated fatty acid peroxidation， iron metabolism control， and antioxidant systems， in order to investigate the association between ferroptosis and GEM resistance mechanisms and provide new directions for the clinical treatment of pancreatic cancer.

     

    • FullText(HTML)
  • loading
    • References(48)
  • [1]
    SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71( 3): 209- 249. DOI: 10.3322/caac.21660.
    [2]
    NEOPTOLEMOS JP, KLEEFF J, MICHL P, et al. Therapeutic developments in pancreatic cancer: Current and future perspectives[J]. Nat Rev Gastroenterol Hepatol, 2018, 15( 6): 333- 348. DOI: 10.1038/s41575-018-0005-x.
    [3]
    JIANG ML, QIAO M, ZHAO CL, et al. Targeting ferroptosis for cancer therapy: Exploring novel strategies from its mechanisms and role in cancers[J]. Transl Lung Cancer Res, 2020, 9( 4): 1569- 1584. DOI: 10.21037/tlcr-20-341.
    [4]
    LEI G, ZHUANG L, GAN BY. Targeting ferroptosis as a vulnerability in cancer[J]. Nat Rev Cancer, 2022, 22( 7): 381- 396. DOI: 10.1038/s41568-022-00459-0.
    [5]
    DIXON SJ, LEMBERG KM, LAMPRECHT MR, et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death[J]. Cell, 2012, 149( 5): 1060- 1072. DOI: 10.1016/j.cell.2012.03.042.
    [6]
    YANG WS, STOCKWELL BR. Ferroptosis: Death by lipid peroxidation[J]. Trends Cell Biol, 2016, 26( 3): 165- 176. DOI: 10.1016/j.tcb.2015.10.014.
    [7]
    WANG YM, WU XR, REN Z, et al. Overcoming cancer chemotherapy resistance by the induction of ferroptosis[J]. Drug Resist Updat, 2023, 66: 100916. DOI: 10.1016/j.drup.2022.100916.
    [8]
    SPRINGFELD C, JÄGER D, BÜCHLER MW, et al. Chemotherapy for pancreatic cancer[J]. Presse Med, 2019, 48( 3 Pt 2): e159- e174. DOI: 10.1016/j.lpm.2019.02.025.
    [9]
    WU S, REN JQ, WU HX, et al. Drug resistance factors in postoperative gemcitabine chemotherapy after radical resection of pancreatic cancer[J]. Chin J Dig Surg, 2023, 22( 5): 616- 622. DOI: 10.3760/cma.j.cn115610-20230323-00125.

    武帅, 任加强, 吴含雪, 等. 胰腺癌根治性切除术后吉西他滨化疗方案耐药因素分析[J]. 中华消化外科杂志, 2023, 22( 5): 616- 622. DOI: 10.3760/cma.j.cn115610-20230323-00125.
    [10]
    von HOFF DD, ERVIN T, ARENA FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine[J]. N Engl J Med, 2013, 369( 18): 1691- 1703. DOI: 10.1056/NEJMoa1304369.
    [11]
    BURRIS HA 3rd, MOORE MJ, ANDERSEN J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial[J]. J Clin Oncol, 1997, 15( 6): 2403- 2413. DOI: 10.1200/JCO.1997.15.6.2403.
    [12]
    BEUTEL AK, HALBROOK CJ. Barriers and opportunities for gemcitabine in pancreatic cancer therapy[J]. Am J Physiol Cell Physiol, 2023, 324( 2): C540- C552. DOI: 10.1152/ajpcell.00331.2022.
    [13]
    BADGLEY MA, KREMER DM, CARLO MAURER H, et al. Cysteine depletion induces pancreatic tumor ferroptosis in mice[J]. Science, 2020, 368( 6486): 85- 89. DOI: 10.1126/science.aaw9872.
    [14]
    SUDA A, UMARU BA, YAMAMOTO Y, et al. Polyunsaturated fatty acids-induced ferroptosis suppresses pancreatic cancer growth[J]. Sci Rep, 2024, 14( 1): 4409. DOI: 10.1038/s41598-024-55050-4.
    [15]
    DOLL S, PRONETH B, TYURINA YY, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition[J]. Nat Chem Biol, 2017, 13( 1): 91- 98. DOI: 10.1038/nchembio.2239.
    [16]
    DIXON SJ, WINTER GE, MUSAVI LS, et al. Human haploid cell genetics reveals roles for lipid metabolism genes in nonapoptotic cell death[J]. ACS Chem Biol, 2015, 10( 7): 1604- 1609. DOI: 10.1021/acschembio.5b00245.
    [17]
    YE Z, HU QS, ZHUO QF, et al. Abrogation of ARF6 promotes RSL3-induced ferroptosis and mitigates gemcitabine resistance in pancreatic cancer cells[J]. Am J Cancer Res, 2020, 10( 4): 1182- 1193.
    [18]
    WU J, MINIKES AM, GAO MH, et al. Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling[J]. Nature, 2019, 572( 7769): 402- 406. DOI: 10.1038/s41586-019-1426-6.
    [19]
    WANG WM, ZHOU X, KONG LM, et al. BUB1 promotes gemcitabine resistance in pancreatic cancer cells by inhibiting ferroptosis[J]. Cancers(Basel), 2024, 16( 8): 1540. DOI: 10.3390/cancers16081540.
    [20]
    PAN H, SUN Y, QIAN LH, et al. A nutrient-deficient microenvironment facilitates ferroptosis resistance via the FAM60A-PPAR axis in pancreatic ductal adenocarcinoma[J]. Research(Wash D C), 2024, 7: 0300. DOI: 10.34133/research.0300.
    [21]
    TESFAY L, PAUL BT, KONSTORUM A, et al. Stearoyl-CoA desaturase 1 protects ovarian cancer cells from ferroptotic cell death[J]. Cancer Res, 2019, 79( 20): 5355- 5366. DOI: 10.1158/0008-5472.CAN-19-0369.
    [22]
    KIM MJ, KIM HS, KANG HW, et al. SLC38A5 modulates ferroptosis to overcome gemcitabine resistance in pancreatic cancer[J]. Cells, 2023, 12( 20): 2509. DOI: 10.3390/cells12202509.
    [23]
    YI JM, ZHU JJ, WU J, et al. Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis[J]. Proc Natl Acad Sci USA, 2020, 117( 49): 31189- 31197. DOI: 10.1073/pnas.2017152117.
    [24]
    YE Z, ZHUO QF, HU QS, et al. FBW7-NRA41-SCD1 axis synchronously regulates apoptosis and ferroptosis in pancreatic cancer cells[J]. Redox Biol, 2021, 38: 101807. DOI: 10.1016/j.redox.2020.101807.
    [25]
    GAO MH, MONIAN P, PAN QH, et al. Ferroptosis is an autophagic cell death process[J]. Cell Res, 2016, 26( 9): 1021- 1032. DOI: 10.1038/cr.2016.95.
    [26]
    HOU W, XIE YC, SONG XX, et al. Autophagy promotes ferroptosis by degradation of ferritin[J]. Autophagy, 2016, 12( 8): 1425- 1428. DOI: 10.1080/15548627.2016.1187366.
    [27]
    ZHOU L, YANG C, ZHONG WL, et al. Chrysin induces autophagy-dependent ferroptosis to increase chemosensitivity to gemcitabine by targeting CBR1 in pancreatic cancer cells[J]. Biochem Pharmacol, 2021, 193: 114813. DOI: 10.1016/j.bcp.2021.114813.
    [28]
    DODSON M, CASTRO-PORTUGUEZ R, ZHANG DD. NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis[J]. Redox Biol, 2019, 23: 101107. DOI: 10.1016/j.redox.2019.101107.
    [29]
    TUERHONG A, XU J, WANG W, et al. CPT1B maintains redox homeostasis and inhibits ferroptosis to induce gemcitabine resistance via the KEAP1/NRF2 axis in pancreatic cancer[J]. Surgery, 2024, 175( 5): 1264- 1275. DOI: 10.1016/j.surg.2023.12.019.
    [30]
    LUO ZY, ZHENG QF, YE SZ, et al. HMGA2 alleviates ferroptosis by promoting GPX4 expression in pancreatic cancer cells[J]. Cell Death Dis, 2024, 15( 3): 220. DOI: 10.1038/s41419-024-06592-y.
    [31]
    ZHU JY, YU ZH, WANG XG, et al. LncRNA MACC1-AS1 induces gemcitabine resistance in pancreatic cancer cells through suppressing ferroptosis[J]. Cell Death Discov, 2024, 10( 1): 101. DOI: 10.1038/s41420-024-01866-y.
    [32]
    NIU ZY, WANG MY, ZHOU L, et al. Elevated GRP78 expression is associated with poor prognosis in patients with pancreatic cancer[J]. Sci Rep, 2015, 5: 16067. DOI: 10.1038/srep16067.
    [33]
    ZHU S, ZHANG QH, SUN XF, et al. HSPA5 regulates ferroptotic cell death in cancer cells[J]. Cancer Res, 2017, 77( 8): 2064- 2077. DOI: 10.1158/0008-5472.CAN-16-1979.
    [34]
    SERRANO-GOMEZ SJ, MAZIVEYI M, ALAHARI SK. Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications[J]. Mol Cancer, 2016, 15: 18. DOI: 10.1186/s12943-016-0502-x.
    [35]
    LIAO TT, YANG MH. Revisiting epithelial-mesenchymal transition in cancer metastasis: The connection between epithelial plasticity and stemness[J]. Mol Oncol, 2017, 11( 7): 792- 804. DOI: 10.1002/1878-0261.12096.
    [36]
    FISCHER KR, DURRANS A, LEE S, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance[J]. Nature, 2015, 527( 7579): 472- 476. DOI: 10.1038/nature15748.
    [37]
    REN YQ, MAO XR, XU H, et al. Ferroptosis and EMT: Key targets for combating cancer progression and therapy resistance[J]. Cell Mol Life Sci, 2023, 80( 9): 263. DOI: 10.1007/s00018-023-04907-4.
    [38]
    ZHAO M, MISHRA L, DENG CX. The role of TGF-β/SMAD4 signaling in cancer[J]. Int J Biol Sci, 2018, 14( 2): 111- 123. DOI: 10.7150/ijbs.23230.
    [39]
    XIA X, WU W, HUANG C, et al. SMAD4 and its role in pancreatic cancer[J]. Tumour Biol, 2015, 36( 1): 111- 119. DOI: 10.1007/s13277-014-2883-z.
    [40]
    CHEN HD, YE Z, HU HF, et al. SMAD4 endows TGF-β1-induced highly invasive tumor cells with ferroptosis vulnerability in pancreatic cancer[J]. Acta Pharmacol Sin, 2024, 45( 4): 844- 856. DOI: 10.1038/s41401-023-01199-z.
    [41]
    MAO XQ, XU J, WANG W, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: New findings and future perspectives[J]. Mol Cancer, 2021, 20( 1): 131. DOI: 10.1186/s12943-021-01428-1.
    [42]
    MAO XQ, XU J, XIAO MM, et al. ARID3A enhances chemoresistance of pancreatic cancer via inhibiting PTEN-induced ferroptosis[J]. Redox Biol, 2024, 73: 103200. DOI: 10.1016/j.redox.2024.103200.
    [43]
    KAMISAWA T, WOOD LD, ITOI T, et al. Pancreatic cancer[J]. Lancet, 2016, 388( 10039): 73- 85. DOI: 10.1016/s0140-6736(16)00141-0.
    [44]
    LIU XX, HUANG ZH, CHEN QZ, et al. Hypoxia-induced epigenetic regulation of miR-485-3p promotes stemness and chemoresistance in pancreatic ductal adenocarcinoma via SLC7A11-mediated ferroptosis[J]. Cell Death Discov, 2024, 10( 1): 262. DOI: 10.1038/s41420-024-02035-x.
    [45]
    LI QY, LIU XW, XIANG FY, et al. Research progress of SLC7A11 in pancreatic cancer[J]. Chin Bull Life Sci, 2022, 34( 7): 815- 820. DOI: 10.13376/j.cbls/2022089.

    李青芸, 刘晓雯, 向凤怡, 等. SLC7A11在胰腺癌中的研究进展[J]. 生命科学, 2022, 34( 7): 815- 820. DOI: 10.13376/j.cbls/2022089.
    [46]
    XU R, YANG J, QIAN Y, et al. Ferroptosis/pyroptosis dual-inductive combinational anti-cancer therapy achieved by transferrin decorated nanoMOF[J]. Nanoscale Horiz, 2021, 6( 4): 348- 356. DOI: 10.1039/d0nh00674b.
    [47]
    ZHAO ZY, WU YJ, LIANG XC, et al. Sonodynamic therapy of NRP2 monoclonal antibody-guided MOFs@COF targeted disruption of mitochondrial and endoplasmic reticulum homeostasis to induce autophagy-dependent ferroptosis[J]. Adv Sci(Weinh), 2023, 10( 30): e2303872. DOI: 10.1002/advs.202303872.
    [48]
    WEI WH. Mechanism of iron death induced by gemcitabine combined with cisplatin in pancreatic cancer[D]. Wuhan: Wuhan University, 2022.

    魏婉慧. 吉西他滨与顺铂联用诱导胰腺癌铁死亡的机制研究[D]. 武汉: 武汉大学, 2022.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (460) PDF downloads(68) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return